Correlation of background parenchymal enhancement on breast MRI with breast cancer.


Journal

Clinical radiology
ISSN: 1365-229X
Titre abrégé: Clin Radiol
Pays: England
ID NLM: 1306016

Informations de publication

Date de publication:
09 2023
Historique:
received: 17 05 2022
revised: 05 03 2023
accepted: 11 05 2023
medline: 7 8 2023
pubmed: 18 6 2023
entrez: 17 6 2023
Statut: ppublish

Résumé

To evaluate the prognostic value of background parenchymal enhancement (BPE) in breast magnetic resonance imaging (MRI) in women referred to radiological department as a high risk for breast cancer. A retrospective, cross-sectional study included 327 consecutive patients (mean age: 60 years, age range: 30-90 years) who underwent breast MRI and tissue biopsy between 2007 and 2016. All MRI images (T1, T2, and subtraction images) were evaluated visually. The relationship of BPE with patient age, fibroglandular tissue (FGT), Breast Imaging Reporting and Data System (BIRADS) categories, presence of breast cancer, and expression of human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR), oestrogen receptor (ER), and Ki67 were analysed. Furthermore, all variables were correlated with pre- and postmenopausal status. BPE of bilateral breast showed a weak correlation with FGT (right BPE: r=-0.14, p=0.004; left BPE: r=0.16, p=0.003), a weak negative correlation with patient age (right BPE: r=-0.14, p=0.007; left BPE: r=-0.15, p=0.006), and significant correlation with HER2 (right BPE, p=0.02), left BPE with HER2 was not significant. Among the correlations between BPE and BIRADS, only between right BPE and right BIRADS was significant (p=0.031). No clear evidence of an association between breast MRI BPE and breast cancer in premenopausal and postmenopausal status was observed, and no difference was found between the right and left breasts. The results of the present study showed no significant correlations between BPE and breast cancer. In addition, there was no significant difference between the right and left breast. Hence, BPE of MRI may not be a reliable biomarker of breast cancer development.

Identifiants

pubmed: 37330320
pii: S0009-9260(23)00218-0
doi: 10.1016/j.crad.2023.05.006
pii:
doi:

Substances chimiques

Receptors, Estrogen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e654-e659

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Auteurs

H Sallam (H)

Department of Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany. Electronic address: sallamhazem@gmail.com.

L Lenga (L)

Department of Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany.

C Solbach (C)

Department Gynaecology and Obstetrics, University Hospital Frankfurt, Frankfurt am Main, Germany.

S Becker (S)

Department Gynaecology and Obstetrics, University Hospital Frankfurt, Frankfurt am Main, Germany.

T J Vogl (TJ)

Department of Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH